Hutton & Hutton Law

Litigation provides remedies for consumers who have been injured through the use of prescription drugs, over-the-counter medications and supplements, and medical device. Growing numbers of consumers are suing manufacturers of drugs and medical devices, alleging that a drug or medical device has damaged their lives and that the risks outweighed its benefits. As Hutton & Hutton investigates these cases we often find that the drug or medical device was marketed to consumers before proper safety testing was performed. We also discover that warnings of severe adverse reactions are either inadequate or never given.

Why Choose Hutton & Hutton?

In excess of 200 verdicts/settlements over One Million Dollars.
Our 7 largest recoveries average over $11 Million.
Multiple settlements involving brain injuries, quadriplegia, paraplegia, wrongful death and other personal injuries arising from defective drugs and medical devices.
One attorney who is also a Registered Nurse.
Our attorneys are licensed to practice in Kansas, Oklahoma, Missouri, Texas, Nevada and Washington, D.C.
Free case review.
No up front money required.
No fees or costs unless we are successful.
Hutton & Hutton is experienced in products liability litigation and has represented many clients across the nation.

If you would like further information regarding our practice, Contact Us.

Pharmaceutical and Device Updates

FDA recalls Hydroxycut products

The U.S. Food and Drug Administration (FDA) is warning consumers to immediately stop using Hydroxycut products, popular dietary supplements used for weight loss, energy enhancers and fat burners, because some Hydroxycut products are associated with a serious number of liver injuries. The FDA has received 23 reports of serious health problems ranging from jaundice and elevated liver enzymes to liver damage requiring liver transplant. The reports include the 2007 death of a 19-year-old man due to liver failure. Other health problems reported include seizures, cardiovascular problems and rhabdomyolysis, a type of muscle damage that can lead to other serious health problems such as kidney failure.

Liver injury, although rare, was reported by patients at the doses of Hydroxycut recommended on the product label. Symptoms of liver injury include jaundice (yellowing of the skin or whites of the eyes) and brown urine. Other symptoms include nausea, vomiting, light-colored stools, excessive fatigue, weakness, stomach or abdominal pain, itching and loss of appetite. If you have experienced any of these symptoms while using Hydroxycut products, contact Hutton & Hutton for a free consultation.

The FDA is warning consumers to immediately stop using 14 Hydroxycut products manufactured by Iovate Health Sciences. Iovate has agreed to recall the following Hydroxycut products:

Hydroxycut Regular Rapid Release Caplets

Hydroxycut Caffeine-Free Rapid Release Caplets

Hydroxycut Hardcore Liquid Caplets

Hydroxycut Max Liquid Caplets

Hydroxycut Regular Drink Packets

Hydroxycut Caffeine-Free Drink Packets

Hydroxycut Hardcore Drink Packets (Ignition Stix)

Hydroxycut Max Drink Packets

Hydroxycut Liquid Shots

Hydroxycut Hardcore RTDs (Ready-to-Drink)

Hydroxycut Max Aqua Shed

Hydroxycut 24

Hydroxycut Carb Control

Hydroxycut Natural

Consumers who have any of the products involved in the recall are advised to stop using them. Hydroxycut Cleanse and Hoodia products are not affected by the recall.

Raptiva -- Psoriasis Drug Withdrawn From Market

On April 8, 2009, Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva (efalizumab), a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare brain infection. By June 8, 2009, Raptiva will no longer be available in the United States. Prescribers are being asked not to initiate Raptiva treatment for any new patients. Prescribers should immediately begin discussing with patients currently using Raptiva how to transition to alternative therapies. The FDA strongly recommends that patients work with their health care professional to transition to alternative therapies for psoriasis.

As of February 2009 there were three confirmed, and one possible report of PML in patients using Raptiva. Symptoms of PML include a new or sudden change in thinking, balance, strength, talking, walking or vision. Call your doctor right away if you have any of these symptoms or if anyone close to you notices a new or sudden change in your thinking. You should also call your doctor to discuss changing to another psoriasis medicine.

Contact Hutton & Hutton for more information.

Reglan -- Black Box Warning

After decades on the market, on February 26, 2009, the FDA ordered manufacturers of the drug Reglan and its generic equivalents, including Metoclopramide hydrochloride, to add a Black Box Warning to their drug labels about the risk of its long-term or high-dose use, and required them to warn patients directly about the potential risks of the drug, especially in light of its limited benefits. Reglan is indicated for short-term treatment of gastroesophageal reflux (GERD) and diabetic gastroparesis, which are chronic conditions. Reglan has also been prescribed for women who are pregnant and experiencing morning sickness, breastfeeding mothers, infants and children and for nausea assocated with migraines. Chronic use of Reglan and other metoclopramide-containing drugs has been linked to Tardive Dyskinesia, a potentially irreversible disorder characterized by involuntary and repetitive movements of the face, tongue and extremities.

Contact Hutton & Hutton for more information.


	©1998-2010 Hutton & Hutton Law Firm, L.L.C. All Rights Reserved. Click for Disclaimer and Privacy Policy. Last modified: 1/7/2010 9:10:31 AM Contact the webmaster.